Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | TERT | O14746 | 1/20 | 0.37 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.36 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.33 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.33 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.33 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.33 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.33 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.33 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | DAO | P14920 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13754062 | 0.74 | IDO1 (0.37) | KMT2ATERTMCL1MAPT | |
| SCHEMBL28360338 | 0.74 | MCL1 (0.46) | KMT2AMCL1DAO | |
| SCHEMBL5317775 | 0.74 | LMNA (0.34) | KMT2AALDH1A1MAPT | |
| SCHEMBL5314215 | 0.72 | UGT2B7 (0.40) | KMT2A | |
| SCHEMBL13760820 | 0.71 | MCL1 (0.47) | KMT2ATERTMCL1GRIN2DGRIN3B | |
| SCHEMBL21795440 | 0.69 | KMT2A (0.50) | KMT2ATERTMCL1ALDH1A1MAPT | |
| SCHEMBL28360301 | 0.68 | MCL1 (0.44) | KMT2ATERTMCL1ALDH1A1MAPT | |
| SCHEMBL5313188 | 0.67 | ESR1 (0.39) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL9887744 | 0.66 | KMT2A (0.55) | KMT2ATERTMCL1ALDH1A1MAPT | |
| SCHEMBL21638930 | 0.66 | KMT2A (0.41) | KMT2ATERTMCL1ALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8314246-B2 | Catalytic reactions involving alkenes | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2012-11-20 | — | — | US | disclosed |
| US-20090216025-A1 | Catalytic reactions involving alkenes | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2009-08-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090216025-A1 | Catalytic reactions involving alkenes | ADH5, ADH1C, ADH1A | KMT2A 1499/4885TERT 175/4885MCL1 3293/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.